Accelerating Medicines Partnership® Program for Common Metabolic Diseases (AMP® CMD)

NIDDK Participation in NIH’s Accelerating Medicines Partnership (AMP) Program

NIDDK is the NIH partner in the Accelerating Medicines Partnership® program for Common Metabolic Diseases (AMP® CMD). Partnering with biopharmaceutical companies and non-profit organizations, this new public-private partnership, managed through the Foundation for the National Institutes of Health (FNIH), is aimed at identifying promising new targets for six common metabolic diseases: nonalcoholic steatohepatitis, kidney diseases, obesity, cardiovascular diseases, type 2 diabetes/prediabetes, and type 1 diabetes.

NIDDK-funded projects will leverage existing genomic association data and integrate new functional genomic data to achieve the following:

• Systematic identification of causal variants at genomic loci associated with common metabolic diseases
• Prioritization of likely effector transcripts functioning at associated genomic loci
• Validation of the role of effector transcripts in disease phenotypes in relevant tissues and cell types
• Generation of pathway networks that incorporate effector transcripts and other genes to clarify their roles in metabolic diseases and to identify common pathways across the diseases
• Creation of data analysis tools to increase usability of large scale functional genomic data generated
• Make all data and analytical tools generated accessible for public use via the online CMD Knowledge Portal External link

About AMP CMD

AMP CMD brings together four biopharmaceutical companies with four teams of NIDDK-funded investigators, including a Knowledge Portal team and Data Coordinating Center. The consortium will capitalize on the enormous amounts of existing genomic data and will generate new largescale molecular data to achieve a deep understanding of genes and pathways that underlie metabolic diseases. Using this information, the consortium will identify and integrate datasets to identify potential biotargets and new therapeutic targets.

AMP CMD Partners

Government

• NIH - NIDDK

Industry

• Amgen
• Eli Lilly and Company
• Novo Nordisk
• Pfizer Inc.

Non-profit Organization

• Foundation for the NIH

Funding Opportunities

NIDDK has solicited participation through the following funding opportunities for AMP

• Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Knowledge Portal (RFA-DK-19-505) NIH external link
• Understanding the Functional Contributions and Mechanisms of Type 2 Diabetes Disease-associated Variants (RFA-DK-19-012) NIH external link

About NIH's AMP initiative

The Accelerating Medicines Partnership program NIH external link is a public-private partnership that incorporates NIH, FDA, biopharmaceutical and life science companies, and non-profit organizations across multiple disease-focused projects. The goal of the partnership in each project is to accelerate the identification of new diagnostics and therapies through expertise and resources shared among partners.

The NIH AMP Program Type 2 Diabetes was active from 2014 to 2021 and its outcomes are now part of AMP CMD.

Accelerating Medicines Partnership and AMP are registered service marks of the U.S. Department of Health and Human Services

Related Links

• NIDDK Active Trials in Diabetes and Endocrine Disease NIH external link

  View related clinical trials from ClinicalTrials.gov.

• Related Study Sections NIH external link

  Study sections conduct initial peer review of applications in a designated scientific area. View related study sections from the NIH's Center for Scientific Review.

Research Resources

NIDDK makes publicly supported resources, data sets, and studies available to researchers to accelerate the rate and lower the cost of new discoveries.

• Ancillary Studies to Major Ongoing Clinical Studies to extend our knowledge of the diseases being studied by the parent study investigators under a defined protocol or to study diseases and conditions not within the original scope of the parent study but within the mission of the NIDDK.
• NIDDK Central Repository for access to clinical resources including data and biospecimens from NIDDK-funded studies.
• NIDDK Information Network (dkNET) External link for simultaneous search of digital resources, including multiple datasets and biomedical resources relevant to the mission of the NIDDK.

Additional Research Programs

 Research TrainingSmall BusinessHuman Subjects ResearchTranslational Research 

NIDDK supports the training and career development of medical and graduate students, postdoctoral fellows, and physician scientists through institutional and individual grants.

Learn about NIDDK Research Training Programs

Meetings & Workshops

dkNET

Supports researchers with tools to enhance scientific rigor, reproducibility, and transparency, and provides a big data knowledge base for genomic and pathway hypothesis generation.

NIH Regional Seminars on Program Funding and Grants Administration

Providing education and training for the next generation of biomedical and behavioral scientist

View all Meetings & Workshops

• 1

View all Meetings & Workshops